Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Strong
Earnings
Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9349.4906
Address
Suite 4 Level 14 350 Collins Street Melbourne, Victoria (VIC) 3000
Description
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.01
Trade Value (12mth)
AU$14,054.00
1 week
-10%
1 month
-10%
YTD
-35.71%
1 year
-43.75%
All time high
1.50
EPS 3 yr Growth
-62.000%
EBITDA Margin
N/A
Operating Cashflow
-$20m
Free Cash Flow Return
-68.60%
ROIC
-47.20%
Interest Coverage
N/A
Quick Ratio
6.20
Shares on Issue (Fully Dilluted)
2503m
HALO Sector
Healthcare
Next Company Report Date
30-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.03
Date | Announcements |
---|---|
24 July 24 |
Alterity Therapeutics to Present at MST Financial Webinar
×
Alterity Therapeutics to Present at MST Financial Webinar |
19 July 24 |
Application for quotation of securities - ATH
×
Application for quotation of securities - ATH |
19 July 24 |
Notice Under Section 708A
×
Notice Under Section 708A |
18 July 24 |
Proposed issue of securities - ATH
×
Proposed issue of securities - ATH |
17 July 24 |
Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
×
Positive Interim Data from ATH434-202 Phase 2 Clinical Trial |
15 July 24 |
Trading Halt
×
Trading Halt |
28 June 24 |
Notification regarding unquoted securities - ATH
×
Notification regarding unquoted securities - ATH |
13 June 24 |
Alterity to Present at Hidden Gems in Life Sciences Webinar
×
Alterity to Present at Hidden Gems in Life Sciences Webinar |
30 May 24 |
Webcast Today - New Data from bioMUSE Natural History Study
×
Webcast Today - New Data from bioMUSE Natural History Study |
21 May 24 |
Notification of cessation of securities - ATH
×
Notification of cessation of securities - ATH |
08 May 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
08 May 24 |
Phase 2 DMC Recommends Continuing Clinical Trial as Planned
×
Phase 2 DMC Recommends Continuing Clinical Trial as Planned |
03 May 24 |
Change in substantial holding
×
Change in substantial holding |
30 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
29 April 24 |
Alterity Presents New Data on ATH434
×
Alterity Presents New Data on ATH434 |
29 April 24 |
Application for quotation of securities - ATH
×
Application for quotation of securities - ATH |
18 April 24 |
Change in substantial holding
×
Change in substantial holding |
17 April 24 |
Alterity Parkinson's and MSA Data Featured at AAN Meeting
×
Alterity Parkinson's and MSA Data Featured at AAN Meeting |
15 April 24 |
Application for quotation of securities - ATH
×
Application for quotation of securities - ATH |
12 April 24 |
Results of Extraordinary General Meeting
×
Results of Extraordinary General Meeting |
12 April 24 |
Options Prospectus
×
Options Prospectus |
10 April 24 |
Alterity to Present New ATH434 Data at Orphan Drug Congress
×
Alterity to Present New ATH434 Data at Orphan Drug Congress |
26 March 24 |
Alterity Receives a $3.9 million R&D Tax Incentive Refund
×
Alterity Receives a $3.9 million R&D Tax Incentive Refund |
25 March 24 |
Change in substantial holding
×
Change in substantial holding |
14 March 24 |
Notice of Extraordinary General Meeting/Proxy Form
×
Notice of Extraordinary General Meeting/Proxy Form |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.